LIGAND PHARMACEUTICALS INCORPORATED Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $4.41 million for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-14.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2016-11-14
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2016-09-30 was $1.42M, a 82.65% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2016-06-30 was $164.00K, a 228.00% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2016-03-31 was $2.83M, a 12.88% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2015-12-31 was $1.77M, a 13.94% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2015 was $5.85M, a 67.42% increase from fiscal 2014.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2014 was $3.49M.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2013 was -$989.00K.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2011 was $17.59M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month as first filed |
|---|---|---|---|---|---|
| 2016-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $1.58M derived: sum of 2 quarters · filed 2016-11-14 | $4.41M 10-Q · filed 2016-11-14 | $6.19M derived: sum of 4 quarters · filed 2016-11-14 | |
| 2016-06-30 | $164.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-11-14 | $2.99M 10-Q · filed 2016-11-14 | $4.77M derived: sum of 3 quarters · filed 2016-11-14 | $5.54M derived: sum of 4 quarters · filed 2016-11-14 | |
| 2016-03-31 | $2.83M 10-Q · filed 2016-11-14 | $4.60M derived: sum of 2 quarters · filed 2016-11-14 | $5.38M derived: sum of 3 quarters · filed 2016-11-14 | $5.43M derived: sum of 4 quarters · filed 2016-11-14 | |
| 2015-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2016-11-14 | $2.55M derived: sum of 2 quarters · filed 2016-11-14 | $2.60M derived: sum of 3 quarters · filed 2016-11-14 | $5.85M 10-K · filed 2016-11-14 | |
| 2015-09-30 | $778.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $828.00K derived: sum of 2 quarters · filed 2015-11-09 | $4.07M 10-Q · filed 2015-11-09 | $5.63M derived: sum of 4 quarters · filed 2015-11-09 | |
| 2015-06-30 | $50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $3.30M 10-Q · filed 2015-08-05 | $4.85M derived: sum of 3 quarters · filed 2015-08-05 | $5.12M derived: sum of 4 quarters · filed 2015-08-05 | |
| 2015-03-31 | $3.25M 10-Q · filed 2015-05-11 | $4.80M derived: sum of 2 quarters · filed 2015-05-11 | $5.07M derived: sum of 3 quarters · filed 2015-05-11 | $5.12M derived: sum of 4 quarters · filed 2015-05-11 | |
| 2014-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-23 | $1.82M derived: sum of 2 quarters · filed 2015-02-23 | $1.88M derived: sum of 3 quarters · filed 2015-02-23 | $3.49M 10-K · filed 2015-02-23 | -$989.00K 10-K · filed 2014-12-01 |
| 2014-09-30 | $268.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | $318.00K derived: sum of 2 quarters · filed 2014-10-31 | $1.94M 10-Q · filed 2014-10-31 | $1.05M derived: sum of 4 quarters · filed 2014-12-12 | |
| 2014-06-30 | $50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $1.67M 10-Q · filed 2014-08-05 | $779.00K derived: sum of 3 quarters · filed 2014-12-12 | $2.37M derived: sum of 4 quarters · filed 2014-12-12 | |
| 2014-03-31 | $1.62M 10-Q · filed 2014-05-07 | $729.00K derived: sum of 2 quarters · filed 2014-12-12 | $2.32M derived: sum of 3 quarters · filed 2014-12-12 | ||
| 2013-12-31 | -$889.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2014-12-12 | $700.00K derived: sum of 2 quarters · filed 2014-12-12 | -$989.00K 10-K/A · filed 2014-12-12 | ||
| 2013-09-30 | $1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | -$100.00K 10-Q · filed 2013-11-08 | |||
| 2013-06-30 | -$1.69M 10-Q · filed 2013-08-01 | ||||
| 2011-12-31 | $17.59M 10-K · filed 2013-03-14 |